Mobia Medical (NASDAQ: MOBI) has announced the publication of two-year follow-up data from the VNS-REHAB study in Neurology, the peer-reviewed journal of the American Academy of Neurology, demonstrating that statistically significant and clinically meaningful improvements in upper-limb motor impairment and function, abilities of daily living, and quality of life were sustained for at least two years following completion of in-clinic Vivistim Paired VNS Therapy.
According to Mobia, with its publication, this data now represents some of the most comprehensive longitudinal evidence to date for any intervention approved for chronic ischemic stroke recovery.
In a statement, Teresa Jacobson Kimberley, PT, PhD, FAPTA, FASNR, a lead researcher on the study and director of the Brain Recovery Lab at the MGH Institute of Health Professions, commented, “What distinguishes Vivistim Therapy from conventional rehabilitation is the ability to actively drive neuroplasticity and enable lasting changes. These two-year outcomes reinforce that the benefits are sustained over a long period of time and, for many individuals, they can continue to accrue. For stroke survivors who have spent years living with impairments, these results open new possibilities for continued recovery, greater independence, improved function, and a better quality of life, even years after their stroke.”
Dr. Christopher Kellner, a cerebrovascular neurosurgeon and Director of the Cerebrovascular Center at the Mount Sinai Health System in New York City noted, “The two-year outcomes published in Neurology are consistent with what I am observing with my own patients since the launch of our Vivistim Program in 2023. Beyond the measurable improvements in upper-limb motor function, patient-reported gains in daily living and quality of life are particularly meaningful. The formal publication of these findings further validates the durability of our observed in-clinic results and, I believe, will help expand access to this technology for more stroke survivors who could benefit.”
Richard Foust, president and CEO of Mobia, added “Publication of these two-year outcomes in Neurology represents an important milestone in the continued development of our clinical evidence base for Vivistim Therapy. At the heart of the data are real people who are regaining function, independence, and quality of life, and that is what drives everything we do. We believe the consistency and durability of our clinical outcomes will continue to strengthen awareness and adoption of Vivistim Therapy by key stakeholders and advance our mission to expand access for the millions of chronic stroke survivors who deserve a better path forward.”
